Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) announced the appointment of Eilon Elmalem as site head of its wholly owned subsidiary Scinai Biopharma Services’ Yavne CDMO facility, effective June 14, 2026. Elmalem, who has supported the company as an external consultant for the past two years, brings more than two decades of biotechnology and pharmaceutical operations experience and will oversee site operations and engineering activities as Scinai continues expanding its contract development and manufacturing platform.
The appointment underscores Scinai's commitment to strengthening its CDMO capabilities, which are central to the company's strategy. The Yavne facility is a key asset for Scinai Biopharma Services, providing development and manufacturing services to other biotechnology and pharmaceutical companies. By appointing an experienced leader like Elmalem, Scinai aims to enhance operational efficiency and drive growth in its CDMO business.
Elmalem's extensive background includes leadership roles in biotech and pharma operations, which will be instrumental in overseeing the site's activities. His previous consultancy work with Scinai has already provided him with deep insight into the company's operations and strategic goals. This familiarity is expected to facilitate a seamless transition and immediate impact on the facility's performance.
The expansion of the CDMO platform is a significant move for Scinai, as it allows the company to leverage its manufacturing expertise to generate revenue and support its own pipeline of immunology therapies. Scinai is advancing a pipeline of therapeutic candidates licensed from the Max Planck Society and from PinCell S.r.l., and the CDMO services provide a complementary revenue stream.
Investors and industry observers will be watching how Elmalem's leadership influences the Yavne facility's output and whether it can attract new clients. The CDMO market is competitive, but Scinai's specialized focus on biopharmaceuticals and its existing infrastructure could provide a competitive edge. For more details on this announcement, visit https://ibn.fm/VLt3w.
Scinai Immunotherapeutics Ltd. is a biopharmaceutical company focused on developing innovative immunology therapies. The company owns Scinai Biopharma Services Ltd., a contract development and manufacturing organization that provides services to biotech and pharma companies. The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI.
